62760-70-7

Basic information

• Product Name: diethyl 2-(hydroxymethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• Synonyms: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2-(hydroxymethyl)-6-methyl-4-(3-nitrophenyl)-, diethyl ester
• CAS NO: 62760-70-7
• Molecular Formula: C₁₉H₂₂N₂O₇
• Molecular Weight: 390.3872
• Mol File: 62760-70-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 551.6°C at 760 mmHg
• Flash Point: 287.4°C
• Density: 1.284g/cm³
• Vapor Pressure: 5.33E-13mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: diethyl 2-(hydroxymethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl 2-(hydroxymethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate(62760-70-7)
• EPA Substance Registry System: diethyl 2-(hydroxymethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate(62760-70-7)

Safety Data

• Hazardous Substances Data: 62760-70-7(Hazardous Substances Data)

Usage

General Description

Diethyl 2-(hydroxymethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate is a chemical compound that belongs to the dihydropyridine class of compounds. It is a derivative of dihydropyridine and contains two ester groups, one hydroxymethyl group, and one nitrophenyl group. Dihydropyridines are known for their vasodilatory and anti-hypertensive properties, and this compound may have similar pharmacological effects. However, its specific biological and pharmacological activities have not been extensively studied, so further research is needed to fully understand its potential uses and effects.

Upstream product

• 10495-09-7 ethyl 4,4-diethoxyacetoacetate 
• 62759-87-9 (E,Z)-ethyl 4,4-diethoxy-2-(3-nitrobenzylidene)acetoacetate 
• 62759-88-0 diethyl 2-diethoxymethyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 99-61-6 3-nitro-benzaldehyde 
• 62760-23-0 diethyl 2-methyl-4-(3-nitrophenyl)-6-formyl-1,4-dihydropyridine-3,5-dicarboxylate 

Downstream Products

• 110645-72-2 diethyl 6-methyl-2-(1-methyltetrazol-5-yl)thiomethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 89267-47-0 ethyl-2-methyl-4-(3-nitrophenyl)-5-oxo-1,4,5,7-tetrahydrofuro<3,4-b>-3-pyridinecarboxylate 
• 74666-23-2 2-Methyl-4-(3-nitro-phenyl)-6-(pyridine-3-carbonyloxymethyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester 
• 105435-14-1 2-chloromethyl-3,5-dicarboethoxy-4-(3-nitrophenyl)-6-methyl-1,4-dihydropyridine 
• 62760-94-5 diethyl-2-acetoxymethyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 

Relevant articles and documents

Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels CaV1.3 and CaV1.2

L-type Ca2+ channels in mammalian brain neurons have either a CaV1.2 or CaV1.3 pore-forming subunit. Recently, it was shown that CaV1.3 Ca2+ channels underlie autonomous pacemaking in adult dopaminergic neurons in the substantia nigra pars compacta, and this reliance renders them sensitive to toxins used to create animal models of Parkinson's disease. Antagonism of these channels with the dihydropyridine antihypertensive drug isradipine diminishes the reliance on Ca2+ and the sensitivity of these neurons to toxins, pointing to a potential neuroprotective strategy. However, for neuroprotection without an antihypertensive side effect, selective CaV1.3 channel antagonists are required. In an attempt to identify potent and selective antagonists of CaV1.3 channels, 124 dihydropyridines (4-substituted-1,4-dihydropyridine-3,5-dicarboxylic diesters) were synthesized. The antagonism of heterologously expressed CaV1.2 and CaV1.3 channels was then tested using electrophysiological approaches and the FLIPR Calcium 4 assay. Despite the large diversity in substitution on the dihydropyridine scaffold, the most CaV1.3 selectivity was only about twofold. These results support a highly similar dihydropyridine binding site at both CaV1.2 and CaV1.3 channels and suggests that other classes of compounds need to be identified for CaV1.3 selectivity.

1,4-Dihydropyridine derivatives, and pharmaceutical method of the same

1,4-dihydropyridine derivatives of the general formula STR1 having vasodilating and anti-hypertensive activity, processes for preparing same, and pharmaceutical compositions thereof for treating cardiovascular diseases.